NCT00622648已完成4 期
International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 8,329
- 试验地点
- 1
- 主要终点
- Death rate with all causes mortality
研究概览
简要总结
The primary objective:
- To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization.
The secondary objective:
- To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization.
- To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalization within 48 hours prior randomization for at least one of the following medical acute medical illness:
- •Acute decompensation of heart failure
- •Severe systemic infection and at least one of the following:
- •Chronic pulmonary diseases (COPD, pulmonary fibrosis, pulmonary restrictive syndrome...)
- •Obesity (BMI ≥ 30kg/m2)
- •Personal history of VTE
- •Age ≥ 60 years
- •Active cancer (defined as being histologically confirmed with an initial diagnosis or recurrence or metastasis within the past 6 months) excluding planned hospitalization for chemotherapy
- •Anticipated duration of hospitalization at least 6 days
- •Health status:
- •ASA Health status score ≤ 3 (American Society of Anesthesiologists)
- •ECOG ≤ 2 in cancer patient
- •Anticipated life expectancy > 1 week
- •Exclusion criteria:
- •Major surgery or major trauma within the previous 6 weeks (orthopedic or trauma surgery to the lower extremities, gastrointestinal tract, urological, chest, gynecological surgery)
- •Need for any ventilatory support (with intubation required)
- •Symptomatic VTE at enrollment
- •Multi organ failure
- •Evidence of an active bleeding disorder
- •Contraindication to anticoagulation:
- •Coagulopathy (acquired or inherited)
- •Neurosurgery within the past day 30
- •History of cerebral hemorrhage at any time
- •Known bacterial endocarditis
- •Uncontrolled arterial hypertension (systolic BP > 200 mmHg or diastolic BP > 110 mm Hg) at 2 successive readings
- •Haemostatic abnormalities: baseline platelet count <50,000/mm3, activated partial thromboplastin time (aPTT) 1.5x the upper limit of normal, or International Normalized Ratio (INR) > 1.5
- •Indication for thrombolytic therapy
- •Need for a curative treatment of anticoagulant therapy (low molecular weight heparin, unfractionated heparin, oral anticoagulant therapy)
- •Receiving LMWH or UFH at prophylactic doses for more than 72 hours prior to inclusion (patients receiving LMWH or UFH at prophylactic doses for 72 hours or less prior to entry may be included in the study)
- •Oral anticoagulant therapy within 72 hours prior to inclusion
- •Cerebrovascular accident at inclusion and within 10 days prior study inclusion
- •Prosthetic heart valves
- •Confirmed cerebral metastases
- •Known hypersensitivity to heparin or LMWH, or pork-derived products
- •History of documented episode of heparin, or LMWH induced thrombocytopenia, and/or thrombosis (HIT, HAT, or HITTS)
- •Participating in another clinical trial within the previous 30 days (patients with cancer included in a cancer treatment protocol are authorized to participate)
- •Persistent renal failure (defined as a documented value of calculated creatinine clearance < 30 mL/min on at least 2 occasions ³3 days prior to entry into the study)
- •Known or suspected severe anemia of unexplained cause considered clinically relevant by investigator
- •Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
- •Unlikely to be compliant (e.g. alcohol, drug abuse)
- •Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling to be tested for pregnancy (pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the investigational product)
- •Refusal or inability to give informed consent to participate in the study
- •Inability to be followed-up after discharge until day 90 after randomization
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
排除标准
- 未提供
研究组 & 干预措施
A
Experimental
Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
干预措施: Enoxaparin (Drug)
B
Placebo Comparator
Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
干预措施: Placebo (Drug)
结局指标
主要结局
Death rate with all causes mortality
时间窗: At day 30
Hemorrhages
时间窗: Occuring until day 90
次要结局
- All-cause mortality(Between randomization and day 90)
- Adverse events, serious adverse events(During the entire observation period (from informed consent signature until Day 90))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)AsthmaNCT00092989Organon and Co650
尚未招募
3 期
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)Advanced Breast CancerNCT05753865CSPC Ouyi Pharmaceutical Co., Ltd.454
已完成
3 期
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseChronic Kidney DiseaseNCT02540993Bayer5,734
已完成
3 期
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)COVIDCOVID-19SARS-CoV-2SARS (Severe Acute Respiratory Syndrome)NCT04546581University of Minnesota593
已完成
3 期
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)Rhinitis, Allergic, SeasonalAsthma, BronchialNCT00092885Organon and Co831